Top

World Journal of Urology

Published in:

01-03-2018 | Original Article

MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1

Authors: Lei Chen, Hongwen Cao, Yigeng Feng

Published in: World Journal of Urology | Issue 3/2018

Abstract

Purpose

Prostate cancer chemoresistance is a major contributor to the poor survival of patients. MicroRNAs (miRNAs) play an important role in regulating cancer resistance. Here we aim to explore the role and mechanism of miR-199a in regulating prostate cancer resistance.

Methods

MiR-199a expressions in human prostate cancer tissues and cell lines were investigated with real-time PCR (RT-PCR). MiR-199a was ectopically overexpressed in PC3 cells, and resistance to paclitaxel (PTX) was evaluated consequently. The interaction between miR-199a and the oncogene Yamaguchi sarcoma viral homolog 1 (YES1) was assessed after miR-199a overexpression. YES1 was ectopically overexpressed, followed by evaluation of PTX resistance. The efficacy of miR-199a as a therapeutic agent was also investigated in vivo.

Results

Downregulation of miR-199a was characteristic of prostate cancer, particularly recurrent cancers. MiR-199a was suppressed in PTX-resistant cell line. Overexpression of miR-199a inhibited PTX resistance. YES1 was a target of miR-199a, and overexpression of YES1 reversed the effect of miR-199a in suppressing PTX resistance. In vivo, miR-199a increased tumor PTX sensitivity.

Conclusions

The downregulation of miR-199a contributes to PTX resistance in prostate cancer. YES1 mediates the regulation of miR-199a in prostate cancer PTX resistance. This miR-199a replacement therapy has potential to overcome PTX resistance.

Available only for authorised users

Pienta KJ, Smith DC (2005) Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 55:300–318CrossRefPubMed

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65:467–479CrossRefPubMed

GrÃ¼nwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M (2002) Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Can Res 62:6141–6145

Hu C-MJ, Zhang L (2012) Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 83:1104–1111CrossRefPubMed

Yang H, Kong W, He L, Zhao J-J, Oâ€™Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV (2008) MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68:425–433CrossRefPubMed

Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S, Majumder S (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283:29897–29903CrossRefPubMedPubMedCentral

Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857–866CrossRefPubMed

Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, Sarkar FH (2010) Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist updates 13:109–118CrossRef

Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L, Gramantieri L (2010) MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 70:5184–5193. https://doi.org/10.1158/0008-5472.CAN-10-0145 CrossRefPubMed

10.

Henry JC, Park JK, Jiang JM, Kim JH, Roberts LR, Nagorney DM, Banerjee S, Schmittgen TD (2011) miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Cancer Res. https://doi.org/10.1158/1538-7445.AM2011-1183

11.

Chen R, Alvero A, Silasi D, Kelly M, Fest S, Visintin I, Leiser A, Schwartz P, Rutherford T, Mor G (2008) Regulation of IKKÎ² by miR-199a affects NF-ÎºB activity in ovarian cancer cells. Oncogene 27:4712–4723CrossRefPubMedPubMedCentral

12.

Yamamoto H, Takeda T, Kanzaki H, Suzawa K, Namba K, Sato H, Torigoe H, Watanabe M, Maki Y, Soh J (2016) Yes1 is the key molecule for the resistance to trastuzumab in breast cancer, and dasatinib overcomes the resistance. AACR. https://doi.org/10.1158/1538-7445.AM2016-4392

13.

Liu L, Yang J, Zhu X, Li D, Lv Z, Zhang X (2016) Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer. FEBS J 283:2326–2339CrossRefPubMed

14.

Giannakakou P, Sackett DL, Kang YK, Zhan ZR, Buters JTM, Fojo T, Poruchynsky MS (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118–17125. https://doi.org/10.1074/jbc.272.27.17118 CrossRefPubMed

15.

Chen D, Guo WJ, Qiu ZP, Wang QF, Li Y, Liang LH, Liu L, Huang SL, Zhao YJ, He XH (2015) MicroRNA-30d-5p inhibits tumour cell proliferation and motility by directly targeting CCNE2 in non-small cell lung cancer. Cancer Lett 362:208–217. https://doi.org/10.1016/j.canlet.2015.03.041 CrossRefPubMed

16.

Carlsson S, Assel M, Sjoberg D, Ulmert D, Hugosson J, Lilja H, Vickers A (2014) Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. Bmj 348:g2296CrossRefPubMedPubMedCentral

17.

Xu N, Zhang JJ, Shen CH, Luo Y, Xia L, Xue F, Xia Q (2012) Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem Biophys Res Commun 423:826–831. https://doi.org/10.1016/j.bbrc.2012.06.048 CrossRefPubMed

18.

Cheng W, Liu T, Wan X, Gao Y, Wang H (2012) MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J 279:2047–2059CrossRefPubMed

19.

Pillai RS (2005) MicroRNA function: multiple mechanisms for a tiny RNA? Rna 11:1753–1761CrossRefPubMedPubMedCentral

20.

Bader AG (2012) miR-34â€”a microRNA replacement therapy is headed to the clinic. Front Genet 3:120CrossRefPubMedPubMedCentral

21.

Bouchie A (2013) First microRNA mimic enters clinic. Nat Res 31(7):577

22.

Kota J, Chivukula RR, Oâ€™Donnell KA, Wentzel EA, Montgomery CL, Hwang H-W, Chang T-C, Vivekanandan P, Torbenson M, Clark KR (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137:1005–1017CrossRefPubMedPubMedCentral

23.

Gandhi NS, Tekade RK, Chougule MB (2014) Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Controll Release 194:238–256CrossRef

Title: MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1
Authors: Lei Chen
Hongwen Cao
Yigeng Feng
Publication date: 01-03-2018
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 3/2018
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-017-2143-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Three- and twelve-month follow-up outcomes of TVT-EXACT and TVT-ABBREVO for treatment of female stress urinary incontinence: a randomized clinical trial

Diagnostic accuracy of C-11 choline and C-11 acetate for lymph node staging in patients with bladder cancer: a systematic review and meta-analysis

Utilization of Active Surveillance and Watchful Waiting for localized prostate cancer in the daily practice

Testicle-sparing surgery versus radical orchiectomy in the management of Leydig cell tumors: results from a multicenter study

Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis

The stone surgeon in the mirror: how are German-speaking urologists treating large renal stones today?